Deals Of The Week: Sandoz/Fougera, Abbott/Action Pharma/Zealand, AstraZeneca/Axerion

 
• By Paul Bonanos, Lisa LaMotta, Jessica Merrill, and Mark Ratner

New company Tolero helps MannKind de-risk a preclinical BTK inhibitor program in a “double-jointed” deal in which the “bio-bucks” eventually could flow in either direction.

More from Archive

More from Pink Sheet